|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3940 USD | +6.78% |
|
-6.24% | -58.71% |
| 10/04 | Jaguar Health, Inc., Q4 2025 Earnings Call, Apr 10, 2026 | |
| 07/04 | Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Capitalization | 48.04L 41.04L 37.84L 35.71L 66.36L 45Cr 68.05L 4.43Cr 1.74Cr 21Cr 1.8Cr 1.76Cr 77Cr | P/E ratio 2026 * |
-3.08x | P/E ratio 2027 * | -1.37x |
|---|---|---|---|---|---|
| Enterprise value | 20.58L 17.58L 16.21L 15.3L 28.43L 19Cr 29.15L 1.9Cr 74.65L 9.2Cr 77.24L 75.6L 33Cr | EV / Sales 2026 * |
0.1x | EV / Sales 2027 * | 0.17x |
| Free-Float |
81.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Jaguar Health, Inc.
| 1 day | +7.59% | ||
| 1 week | -6.24% | ||
| Current month | +3.78% | ||
| 1 month | -23.56% | ||
| 3 months | -44.36% | ||
| 6 months | -81.95% | ||
| Current year | -58.71% |
| 1 week | 0.34 |  | 0.45 |
| 1 month | 0.31 | | 0.54 |
| Current year | 0.31 | | 1.87 |
| 1 year | 0.31 | | 15.48 |
| 3 years | 0.31 | | 1,830 |
| 5 years | 0.31 | | 7,69,490.38 |
| 10 years | 0.31 | | 10,00,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lisa Conte
CEO | Chief Executive Officer | 67 | 06/06/2013 |
Carol Lizak
DFI | Director of Finance/CFO | 62 | 13/08/2019 |
Jonathan Wolin
CMP | Compliance Officer | 64 | 01/11/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Lisa Conte
BRD | Director/Board Member | 67 | 06/06/2013 |
James Bochnowski
CHM | Chairman | 82 | 01/06/2014 |
John Micek
BRD | Director/Board Member | 73 | 01/04/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.78% | -6.24% | -92.62% | -99.96% | 48.04L | |
| -1.27% | +0.25% | +23.20% | +147.74% | 84TCr | |
| -1.15% | -2.26% | +52.58% | +41.79% | 57TCr | |
| -2.21% | -1.54% | +13.62% | +25.08% | 37TCr | |
| +0.32% | -0.75% | +29.45% | +14.60% | 32TCr | |
| -1.59% | +0.20% | +45.23% | +25.78% | 32TCr | |
| -1.74% | -1.22% | +50.78% | +3.28% | 30TCr | |
| -0.94% | +0.68% | +35.93% | +38.47% | 29TCr | |
| -1.50% | +0.92% | +17.62% | +37.50% | 19TCr | |
| -1.04% | -1.70% | +29.34% | +65.43% | 17TCr | |
| Average | -0.34% | -1.13% | +20.51% | +29.97% | 33.78TCr | |
| Weighted average by Cap. | -1.23% | -0.42% | +33.38% | +59.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.05Cr 1.75Cr 1.61Cr 1.52Cr 2.83Cr 191.62Cr 2.9Cr 19Cr 7.42Cr 92Cr 7.68Cr 7.52Cr 326.89Cr | 1.41Cr 1.21Cr 1.11Cr 1.05Cr 1.95Cr 132.16Cr 2Cr 13Cr 5.12Cr 63Cr 5.3Cr 5.18Cr 225.45Cr |
| Net income | -18.76L -16.03L -14.78L -13.95L -25.91L -18Cr -26.57L -1.73Cr -68.05L -8.39Cr -70.4L -68.91L -30Cr | -55.17L -47.13L -43.46L -41.01L -76.21L -52Cr -78.14L -5.09Cr -2Cr -25Cr -2.07Cr -2.03Cr -88Cr |
| Net Debt | -27.46L -23.46L -21.63L -20.41L -37.93L -26Cr -38.89L -2.53Cr -99.6L -12Cr -1.03Cr -1.01Cr -44Cr | -24.73L -21.13L -19.48L -18.38L -34.16L -23Cr -35.03L -2.28Cr -89.7L -11Cr -92.81L -90.84L -40Cr |
Employees
49
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 0.3858 $ | +4.57% | 10,82,788 |
| 10/26/10 | 0.3690 $ | -2.64% | 4,99,829 |
| 09/26/09 | 0.3790 $ | -5.01% | 7,06,029 |
| 08/26/08 | 0.3990 $ | -2.56% | 16,42,676 |
| 07/26/07 | 0.4095 $ | -0.15% | 4,15,532 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3690USD
Average target price
7.500USD
Spread / Average Target
+1,932.52%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JAGX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition